Marie-Luise Buchholtz1, Ansgar Brüning, Ioannis Mylonas, Julia Jückstock. 1. Division of Infectious Diseases in Gynaecology and Obstetrics, First Department of Obstetrics and Gynaecology, Ludwig-Maximilians-University Munich, Maistrasse 11, 80337, Munich, Germany.
Abstract
PURPOSE: Due to very unspecific symptoms ovarian cancer often is diagnosed only at a late stage of the disease. Thus, morbidity and mortality of the patients are high. Even the established tumor marker CA12-5 shows only low specificity, rising the need for alternative biomarkers capable of detecting early stages of ovarian cancer. We analyzed the expression of the tumor suppressor candidate gene LDOC1 (leucine zipper downregulated in cancer 1) as a potential early biomarker in ovarian cancer cell lines. METHODS: A total of seven ovarian cancer cell lines were analyzed by RT-PCR (reverse transcriptase polymerase chain reaction) and real-time PCR for expression of LDOC1. Verification of promoter methylation was performed using methylation-specific primers on bisulfite-modified genomic DNA. RESULTS: Three out of seven ovarian cancer cell lines showed a complete loss of LDOC1 gene expression. LDOC1 silencing was caused neither by gene deletion nor gene rearrangements, but by methylation and subsequent inactivation of the concerned promoter as proofed by methylation specific primers. Similarly, promoter methylation could be inhibited by adding AdC (5-aza-2'-deoxycytidine), an inhibitor of DNA methyltransferases. As a result, a reactivation of the LDOC1 gene was seen. CONCLUSIONS: The tumor suppressor gene LDOC1 in ovarian cancer cell lines is downregulated by promoter methylation and thus may serve as an early biomarker. Further investigation will show if detection of methylated LDOC1 in peripheral blood has both adequate sensitivity and specificity for a timely non-invasive detection of ovarian cancer.
PURPOSE: Due to very unspecific symptoms ovarian cancer often is diagnosed only at a late stage of the disease. Thus, morbidity and mortality of the patients are high. Even the established tumor marker CA12-5 shows only low specificity, rising the need for alternative biomarkers capable of detecting early stages of ovarian cancer. We analyzed the expression of the tumor suppressor candidate gene LDOC1 (leucine zipper downregulated in cancer 1) as a potential early biomarker in ovarian cancer cell lines. METHODS: A total of seven ovarian cancer cell lines were analyzed by RT-PCR (reverse transcriptase polymerase chain reaction) and real-time PCR for expression of LDOC1. Verification of promoter methylation was performed using methylation-specific primers on bisulfite-modified genomic DNA. RESULTS: Three out of seven ovarian cancer cell lines showed a complete loss of LDOC1 gene expression. LDOC1 silencing was caused neither by gene deletion nor gene rearrangements, but by methylation and subsequent inactivation of the concerned promoter as proofed by methylation specific primers. Similarly, promoter methylation could be inhibited by adding AdC (5-aza-2'-deoxycytidine), an inhibitor of DNA methyltransferases. As a result, a reactivation of the LDOC1 gene was seen. CONCLUSIONS: The tumor suppressor gene LDOC1 in ovarian cancer cell lines is downregulated by promoter methylation and thus may serve as an early biomarker. Further investigation will show if detection of methylated LDOC1 in peripheral blood has both adequate sensitivity and specificity for a timely non-invasive detection of ovarian cancer.
Authors: Michele Salemi; Nunziata Barone; Sandro La Vignera; Rosita A Condorelli; Domenico Recupero; Antonio Galia; Filippo Fraggetta; Anna Maria Aiello; Pietro Pepe; Roberto Castiglione; Enzo Vicari; Aldo E Calogero Journal: Oncol Lett Date: 2016-08-10 Impact factor: 2.967
Authors: Giulia Wanka; Elisa Schmoeckel; Doris Mayr; Sophie Fuerst; Christina Kuhn; Sven Mahner; Julia Knabl; Maria Margarete Karsten; Christian Dannecker; Helene H Heidegger; Aurelia Vattai; Udo Jeschke; Julia Jueckstock Journal: Int J Mol Sci Date: 2020-12-05 Impact factor: 5.923
Authors: Andrea M Griesinger; Davis A Witt; Sydney T Grob; Sabrina R Georgio Westover; Andrew M Donson; Bridget Sanford; Jean M Mulcahy Levy; Randall Wong; Daniel C Moreira; John A DeSisto; Ilango Balakrishnan; Lindsey M Hoffman; Michael H Handler; Kenneth L Jones; Rajeev Vibhakar; Sujatha Venkataraman; Nicholas K Foreman Journal: Neuro Oncol Date: 2017-10-01 Impact factor: 12.300